RSS   Newsletter   Contact   Advertise with us

Blueprint Medicines Corporation Q2 revenues

Christian Fernsby ▼ | July 30, 2020
Blueprint Medicines Corporation reported financial results for the second quarter ended June 30, 2020.
Blueprint Medicines Corporation
Blueprint Medicines Corporation   Revenues were $8.3 million for the second quarter of 2020
Revenues were $8.3 million for the second quarter of 2020, including $5.7 million of net product revenues from sales of AYVAKIT.

Topics: Blueprint Medicines Corporation

Cost of sales was $0.1 million for the second quarter of 2020. Blueprint Medicines did not incur cost of sales in the second quarter of 2019 as no product sales were generated during that period.

Net loss was $123.5 million for the second quarter of 2020 as compared to a net loss of $99.7 million for the second quarter of 2019.

As of June 30, 2020, cash, cash equivalents and investments were $650.3 million.


 

MORE INSIDE POST